The use of this website is governed by the Terms of Use. By clicking "I agree" you agree to our use of cookies. Box 30170 College Station, TX 77842-3170 T: 1- 877-373-6374 (US, Canada, Puerto Rico)1-781-575-3100 (non-US) web.queries@computershare.com www.computershare.com/investor. investor relations. You can learn more about our use of cookies and similar technologies and your choices by reviewing our Cookies Policy. Maria Kelman Director of Investor Relations T: +1-857-362-9635 kelman@pieris.com, Transfer Agent Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA, including with respect to the additional in-use and compatibility study for PRS-343, and the resolution of the partial clinical hold relating to that drug candidate; competition in the industry in which we operate; delays or disruptions due to COVID-19; and market conditions. 9th floor Boston, MA 02109, Investor Relations SOURCE: Pieris Pharmaceuticals, Inc. contact us. The following slide deck was published by Pieris Pharmaceuticals, Inc. in … Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 … Investor Contacts. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman. Argot Partners (617) 340-6075 joseph@argotpartners.com useful links. To access the call, participants may dial 1-877-407-8920 (US & Canada) or 1-412-902-1010 (International) at least 10 minutes prior to the start of the call. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and the Company's Quarterly Reports on Form 10-Q. corporate info. Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences Download PDF BOSTON,MA / ACCESSWIRE /November 10,2020 / Pieris … PIERIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) Investor Relations Contact: Pieris Pharmaceuticals, Inc. ... Director of Investor Relations +1 857 362 9635. kelman@pieris.com. Investor email alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. useful links. Contact Investor Relations . 255 State Street From philanthropic efforts to advocacy initiatives, we are living our values throughout our communities. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. You can learn more about our use of cookies and similar technologies and your choices by reviewing our Cookies Policy. Transfer Agent. Annual Reports : Access the latest Richard Pieris and Company PLC Annual Report and past Annual Reports. BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, … Find the latest SEC Filings data for Pieris Pharmaceuticals, Inc. Common Stock (PIRS) at Nasdaq.com. Pieris Pharmaceuticals, Inc. Investor Relations. Investor Relations Maria Kelman Director of Investor Relations T: +1-857-362-9635 kelman@pieris.com. Anticalin® is a registered trademark of Pieris. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. PIERIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) The Investor Relations website contains information about Pilgrim's Pride Corporation's business for stockholders, potential investors, and financial analysts. T: 281-589-5200 IR@callon.com. Computershare P.O. Daniel J. Speciale Vice President, Finance and Investor Relations Officer. In 2017, Pieris forged strategic alliances with Servier and AstraZeneca to accelerate its transformation into a fully-integrated, biologics R&D and commercial organization, focused on two immunology-related therapeutic areas: immuno-oncology and respiratory disease. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. SOURCE: Pieris Pharmaceuticals, Inc. As an MLP, PAA makes quarterly distributions of its available cash to Unitholders of record. Richard Pieris and Company PLC Interim Reports : Year 2020-21. An archived replay of the call will be available for 30 days by dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415 (International) and providing the Conference ID #13661472. American Stock Transfer & Trust Company, LLC Attn. financial reporting. The use of this website is governed by the Terms of Use. Our libraries of more than 100 billion different Anticalin proteins can virtually bind to any target of interest, Corporate Address: The reports are in Adobe Acrobat format and may be downloaded or opened by clicking the links below. investor.relations@mnk.com. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. Actual results could differ from those projected in any forward-looking statements due to numerous factors. investor relations. Such forward-looking statements include, among other things, the timing for, and outcome of, the additional in-use and compatibility study for PRS-343 as requested by the FDA; whether data from patients enrolled to date will be sufficient to inform the recommended phase 2 dose for the Company's planned proof of concept study of PRS-343 in gastric cancer; the expected timing and potential outcomes of the reporting by the Company of key clinical data from its programs, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic and the expected timing for reporting data, making IND filings or achieving other milestones related to our programs, including PRS-060/AZD1402, PRS-343, PRS-344, and PRS-352 and the expected timing of the initiation of the next stage of PRS-343's development in gastric cancer. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. Learn More. Pieris Pharmaceuticals, Inc.Maria KelmanDirector of Investor Relations+1 857 362 9635kelman@pieris.com. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. Shareholder Services Department 6201 15th Avenue Brooklyn, New York 11219 T: 800-937-5449 help@astfinancial.com www.amstock.com. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. More than 150 years of quality, integrity and service. To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call. The foundation of Pieris' partnerships and R&D efforts is a proprietary class of clinically-tested next generation therapeutics, Anticalin proteins. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. Building On Our Heritage. © 2020, All Rights Reserved for Pieris | Powered by. Anticalin proteins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Use of cookies on this website: This website uses cookies to give you the best user experience, for analytics, and improvement of functionalities of this website and third party sites. Pieris Pharmaceuticals, Inc. today announced that it will host a second quarter 2020 investor call on Monday, August 10, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update. Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.16. Joe Rayne. Use of cookies on this website: This website uses cookies to give you the best user experience, for analytics, and improvement of functionalities of this website and third party sites. Pieris Pharmaceuticals to Host Third Quarter... https://www.accesswire.com/612696/Pieris-Pharmaceuticals-to-Host-Third-Quarter-2020-Investor-Call-and-Corporate-Update-on-November-4-2020. Investor Relations Contact: Pieris Pharmaceuticals, Inc. ... Director of Investor Relations +1 857 362 9635. kelman@pieris.com. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman : Director of Investor Relations +1 857 362 9635 kelman@pieris.com : SOURCE: Pieris Pharmaceuticals, Inc. BOSTON, MA / ACCESSWIRE / May 4, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2020 investor call on Monday, May 11, 2020 at 8:00 … For more information, visit www.pieris.com. By clicking "I agree" you agree to our use of cookies. financial reporting. Investor Relations (781) 292-4279 info@verastem.com. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate update. investor relations - reports. Corporate Address: Pieris Pharmaceuticals, Inc. 255 State Street 9th floor Boston, MA 02109. Our Culture. Plains All American Pipeline (NYSE: PAA) Plains All American Pipeline is a publicly traded master limited partnership (“MLP”). Pieris will host an investor conference call on Thursday, January 5, 2017 at 8:30 AM (EST) to discuss the collaboration. Transfer Agent Computershare P.O. Investor Relations. BOSTON, MA / ACCESSWIRE / September 3, 2020 / Pieris, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor … Statements in this press release that are not purely historical are forward-looking statements. After submitting your request, you will receive an activation email to the requested email address. Investor Relations Institutional Ownership and Shareholders Pieris Pharmaceuticals, Inc. (US:PIRS) has 201 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). © 2020, All Rights Reserved for Pieris | Powered by, 3rd Annual Evercore ISI HealthCONx Conference, Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences, Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update, Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020. SOURCE: Pieris Pharmaceuticals, Inc. contact us. By using this website you acknowledge that you have read the Privacy Policy and Terms of Use and the disclaimers and caveats contained therein and you accept and agree to be bound by the terms thereof. By using this website you acknowledge that you have read the Privacy Policy and Terms of Use and the disclaimers and caveats contained therein and you accept and agree to be bound by the terms thereof. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Investor Contact. investor relations - reports. Director of Investor Relations +1 857 362 9635. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. corporate info. BOSTON, MA / ACCESSWIRE / September 3, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor … Pieris Pharmaceuticals (PIRS) Investor Presentation - Slideshow. Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing to providing novel solutions for oncology, respiratory disease and other therapeutic areas by applying its proprietary Anticalin® technology to create differentiated drugs. This compares to … John Doyle.